These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24505851)

  • 1. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
    Carver KH; Elikan J; Lietzan E
    Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
    Levi EL
    Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exclusivity strategies and opportunities in view of the Biologics Price Competition and Innovation Act.
    Gaudry KS
    Food Drug Law J; 2011; 66(4):587-630, ii. PubMed ID: 24505830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic considerations under the Biologics Price Competition and Innovation Act.
    Marquardt JL; Auten SR
    Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Case for Disclosure of Biologics Manufacturing Information.
    Heled Y
    J Law Med Ethics; 2019 Dec; 47(4_suppl):54-78. PubMed ID: 31955690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar Makers Hope Court Starts 6-Month Wait Sooner.
    Silverman E
    Manag Care; 2017 Mar; 26(3):31. PubMed ID: 28510518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
    Chen BK; Yang YT; Bennett CL
    Drugs; 2018 Nov; 78(17):1777-1781. PubMed ID: 30446980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting Trade Secrets in Canada.
    Courage N; Calzavara J
    Cold Spring Harb Perspect Med; 2015 May; 5(9):a024489. PubMed ID: 25986591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.
    Feldman R
    PLoS Med; 2024 Apr; 21(4):e1004381. PubMed ID: 38662775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.